Silexion Therapeutics Corp (SLXN) is the subject of a Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership. As of the close of business on August 18, 2026, they may be deemed to beneficially own 286,866 Ordinary Shares, including shares underlying several warrants, representing 4.99% of Silexion’s Ordinary Shares. This position reflects a Securities Purchase Agreement dated August 11, 2026 and multiple Intracoastal warrants that contain blocker provisions limiting exercises so that the Reporting Persons’ beneficial ownership does not exceed specified percentage thresholds (primarily 4.99% or 9.99%). All voting and dispositive power is reported as shared, with no sole power over the shares.
Silexion Therapeutics Corp reported larger losses for the three and six months ended June 30, 2026 while advancing its lead RNAi candidate SIL204 into an active Phase 2/3 trial in locally advanced pancreatic cancer. Regulatory approvals in Israel and from Germany’s BfArM enabled trial initiation, with the first site activated at Tel Aviv Sourasky Medical Center in July 2026 and additional Israeli and German sites progressing toward activation. New preclinical immuno-oncology data showed statistically significant effects on MHC-I, FAS (CD95), and HLA-G across four KRAS mutations, supporting future combination with anti-PD-(L)1 checkpoint inhibitors.
R&D expenses rose to $2.2 million in the quarter and $3.6 million year-to-date, driving a net loss of $3.6 million for the quarter and $6.3 million for the six months. Cash and cash equivalents declined to $2.2 million and total assets to $4.2 million, while shareholders’ equity narrowed to $44 thousand. The company executed multiple capital-structure actions, including a 1-for-10 reverse split and a registered public offering with $2.5 million gross proceeds and approximately $2.1 million net proceeds, and highlighted substantial doubt about its ability to continue as a going concern in its financial statements.
Silexion Therapeutics Corp reported updated historical financials to reflect a previously approved 1-for-10 reverse share split, on top of earlier 1-for-9 and 1-for-15 splits. All shares, per‑share data, options and warrants for 2024–2025 and March 31, 2026 have been retroactively adjusted.
For 2025, Silexion, a clinical‑stage RNAi oncology company with no revenues, recorded a net loss of $11.9 million and negative operating cash flow of $10.8 million. Cash and cash equivalents were $6.0 million and total assets $7.2 million as of December 31, 2025, against an accumulated deficit of $55.2 million. Shareholders’ equity improved from a deficit of $4.0 million at year‑end 2024 to positive equity of $2.6 million, mainly through public offerings, warrant exercises and note conversions.
The independent auditor issued an unqualified opinion but highlighted substantial doubt about Silexion’s ability to continue as a going concern, citing recurring operating losses, negative operating cash flows and limited liquidity. Management discloses that existing cash is expected to fund operations for only several months from the financial statement issuance date and that additional financing will be required.
Silexion Therapeutics Corp completed a best-efforts public offering of equity and warrants. The company sold 2,028,619 ordinary shares, 1,817,542 pre-funded warrants and 3,846,161 Series E ordinary warrants at a combined price of $0.65 per share and accompanying warrant (and $0.6499 per pre-funded warrant and accompanying warrant), generating approximately $2.5 million in gross proceeds and about $2.1 million in net proceeds. The Series E warrants are immediately exercisable at $0.65 per share for five years; the pre-funded warrants are exercisable at $0.0001 per share until fully exercised.
The company also issued 269,231 placement agent warrants at an exercise price of $0.8125 and paid the placement agent an 8% combined cash and management fee plus expenses. In connection with the closing, Silexion converted $750,001 of its sponsor note into 1,153,848 ordinary shares at $0.65 per share, reducing the note balance to $206,462. After the offering, note conversion, ATM sales and pre-funded warrant exercises, Silexion preliminarily estimates shareholders’ equity at approximately $3.2 million, and plans to use the proceeds primarily to advance its SIL204 clinical trial and for general corporate purposes.
Silexion Therapeutics Corp received an updated ownership report from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on June 30, 2026, the reporting persons state they may be deemed to have beneficial ownership of no Ordinary Shares, representing 0.0% of the outstanding class. They hold two warrants for 32,500 and 38,920 Ordinary Shares, respectively, but these are not exercisable until stockholder approval of the underlying share issuances and each is subject to a 9.99% beneficial ownership blocker. Without these blocker provisions and assuming exercisability, they indicate potential beneficial ownership of 71,420 Ordinary Shares, yet currently report no voting or dispositive power over any shares.
Silexion Therapeutics Corp, a Cayman Islands clinical-stage oncology company focused on RNA interference therapies for KRAS-driven cancers, has filed an amended Form S-1 for a primary best-efforts offering of up to 2,673,796 ordinary shares, each sold together with one ordinary warrant. Investors who would otherwise exceed 4.99% (or 9.99%) ownership may instead buy pre-funded warrants, priced at an assumed $1.8699 with a $0.0001 exercise price, each paired with an ordinary warrant.
Assuming the maximum shares are sold at an assumed $1.87 per share and no pre-funded warrants or warrant exercises, Silexion estimates net proceeds of about $4.3 million to fund pre-clinical and clinical studies, including its Phase 2/3 trial of lead candidate SIL204 in locally advanced pancreatic cancer, and for general corporate purposes. There is no minimum offering amount and no escrow, and H.C. Wainwright & Co. is acting as exclusive placement agent on a reasonable best-efforts basis.
The company had $2.4 million in cash and an accumulated deficit of $57.9 million as of March 31, 2026, with its auditor raising substantial doubt about its ability to continue as a going concern. Silexion is also working to restore and maintain compliance with the Nasdaq Capital Market’s $2.5 million shareholders’ equity requirement, and warns that failure to do so could lead to delisting.
Silexion Therapeutics Corp furnished an updated corporate presentation outlining development plans for its lead siRNA oncology candidate SIL204, which targets KRAS-driven tumors such as locally advanced pancreatic cancer. The program’s Phase 2/3 clinical trial in locally advanced pancreatic cancer was initiated in July 2026 after regulatory approvals in Israel and Germany, using a dual intratumoral and subcutaneous dosing strategy.
The presentation highlights preclinical data showing broad KRAS silencing at sub-nanomolar concentrations, tumor growth inhibition in mouse models, and established safety margins of up to 11-fold over the clinical starting dose in GLP toxicology studies with no systemic organ toxicity. The Phase 2/3 design includes a small safety run-in (about 15–18 patients) followed by randomized segments enrolling approximately 166 and 222 patients. Early human data are expected in Q4 2026, with an IND submission planned for Q1 2027 to expand the program to the U.S. and additional EU countries.
Silexion Therapeutics Corp. is a clinical-stage oncology biotech developing RNA interference therapies for KRAS-driven cancers. Lead candidate SIL204, a second-generation siRNA for locally advanced pancreatic cancer, combines intratumoral and subcutaneous dosing with chemotherapy. Regulators in Israel and Germany approved initiation of a Phase 2/3 trial, and the first site in Tel Aviv began operations in late July 2026.
The company plans a best-efforts primary offering of units consisting of ordinary shares or pre-funded warrants, each paired with an ordinary warrant, plus placement agent warrants, and is registering the ordinary shares underlying these instruments. Ordinary shares and publicly traded warrants list on Nasdaq as “SLXN” and “SLXNW”; on August 6, 2026 they closed at $1.79 and $0.020, with 1,349,019 ordinary shares outstanding before the offering.
Silexion is pre-revenue and reported a net loss of $11.9 million in 2025 and $2.7 million for the quarter ended March 31, 2026, with an accumulated deficit of $57.9 million and cash of $2.4 million. Auditors highlighted substantial doubt about its ability to continue as a going concern. The company has relied on multiple reverse share splits, warrant inducement financings, and conversions of a sponsor promissory note originally totaling $3.433 million (reduced to $956 thousand) to restore and maintain Nasdaq listing compliance, and it expects to need substantial additional capital.
Silexion Therapeutics Corp reported new preclinical data for SIL204, an RNAi therapy targeting KRAS-driven cancers. In human pancreatic and non-small cell lung cancer cell lines with KRAS G12D, G12V, and G12C mutations, SIL204 increased expression of the immune death receptor FAS and reduced expression of the immune checkpoint HLA-G, both in a statistically significant, dose-dependent manner.
Together with previously reported MHC-I upregulation in KRAS G12R-mutant pancreatic cells, the findings suggest a coordinated immune-sensitization profile across four KRAS mutations and three immune pathways: antigen presentation, apoptosis sensitivity, and checkpoint reduction. Silexion is advancing SIL204 into Phase 2/3 clinical evaluation, following initiation of its first clinical trial site at Tel Aviv Sourasky Medical Center in July 2026.
Silexion Therapeutics Corp reported changes to its Board and audit committee. Professor Amnon Peled notified the Board of his resignation from the Board and all committees, including the audit committee, effective August 1, 2026. His resignation was for personal reasons and did not result from any disagreement regarding the company’s operations, policies, or practices.
Immediately upon his resignation becoming effective, the Board appointed existing independent director Avner Lushi to the audit committee, filling the vacancy. The Board determined that Lushi meets the independence standards of Nasdaq Listing Rule 5605(c)(2)(A) and SEC Rule 10A-3(b)(1). With his appointment, the audit committee now consists of three independent members—Dror J. Abramov (chair and audit committee financial expert), Ruth Alon, and Lushi—restoring full compliance with Nasdaq’s audit committee composition requirements without using the cure period.